Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-5 Year Investment Grade Corporate Bond ETF
IGSB
|
+$596M |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$429M |
| 3 |
Verizon
VZ
|
+$399M |
| 4 |
Amgen
AMGN
|
+$214M |
| 5 |
Citizens Financial Group
CFG
|
+$212M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MBS ETF
MBB
|
+$561M |
| 2 |
iShares National Muni Bond ETF
MUB
|
+$535M |
| 3 |
Oracle
ORCL
|
+$144M |
| 4 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$143M |
| 5 |
Vanguard Mortgage-Backed Securities ETF
VMBS
|
+$141M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.17% |
| 2 | Financials | 13.07% |
| 3 | Healthcare | 12.05% |
| 4 | Consumer Discretionary | 10.98% |
| 5 | Industrials | 9.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SPRB
3176
Spruce Biosciences
SPRB
$114M
| $485K | ﹤0.01% |
576
-13
| -2% | -$13.9K |
|
3177
Immunic
IMUX
$178M
| $484K | ﹤0.01% |
3,946
+2,134
| +118% | +$295K |
|
3178
Lifetime Brands
LCUT
$192M
| $484K | ﹤0.01% |
32,293
+2,160
| +7% | +$33.1K |
|
3179
Oil-Dri
ODC
$1.43B
| $484K | ﹤0.01% |
28,292
| – | – |
|
3180
INNOVATE Corp
VATE
$106M
| $482K | ﹤0.01% |
12,087
-796
| -6% | -$32.2K |
|
3181
Safe Bulkers
SB
$772M
| $474K | ﹤0.01% |
118,199
+8,117
| +7% | +$28.4K |
|
|
MRLN
3182
DELISTED
Marlin Business Services Corp
MRLN
| $474K | ﹤0.01% |
20,826
-1,387
| -6% | -$29.1K |
|
3183
Voyager Therapeutics
VYGR
$181M
| $472K | ﹤0.01% |
114,256
-50,623
| -31% | -$229K |
|
|
SGTX
3184
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
| $471K | ﹤0.01% |
3,375
-431
| -11% | -$75.7K |
|
3185
EyePoint Inc
EYPT
$999M
| $470K | ﹤0.01% |
+52,273
| New | +$502K |
|
3186
Celcuity
CELC
$4.06B
| $466K | ﹤0.01% |
+19,405
| New | +$499K |
|
3187
NACCO Industries
NC
$359M
| $464K | ﹤0.01% |
17,810
-5,381
| -23% | -$134K |
|
3188
KVH Industries
KVHI
$171M
| $459K | ﹤0.01% |
37,243
-2,391
| -6% | -$32.3K |
|
|
JOAN
3189
DELISTED
JOANN, Inc. Common Stock
JOAN
| $456K | ﹤0.01% |
+28,949
| New | +$396K |
|
|
FRBK
3190
DELISTED
Republic First Bancorp Inc
FRBK
| $456K | ﹤0.01% |
114,232
| – | – |
|
|
SCWX
3191
DELISTED
SecureWorks Corp Class A Common Stock
SCWX
| $450K | ﹤0.01% |
24,237
+4,602
| +23% | +$71.6K |
|
3192
Western New England Bancorp
WNEB
$259M
| $449K | ﹤0.01% |
55,016
-2,518
| -4% | -$20.8K |
|
|
CODX
3193
Co-Diagnostics
CODX
$5.56M
| $446K | ﹤0.01% |
1,801
-1,909
| -51% | -$491K |
|
3194
Greenwich LifeSciences
GLSI
$188M
| $442K | ﹤0.01% |
+9,819
| New | +$371K |
|
3195
Paysign
PAYS
$517M
| $438K | ﹤0.01% |
137,725
-78,224
| -36% | -$281K |
|
|
HOOK
3196
DELISTED
HOOKIPA Pharma
HOOK
| $437K | ﹤0.01% |
4,769
+995
| +26% | +$133K |
|
3197
Elicio Therapeutics
ELTX
$75.9M
| $433K | ﹤0.01% |
3,321
-161
| -5% | -$23.2K |
|
|
MBII
3198
DELISTED
Marrone Bio Innovations, Inc.
MBII
| $428K | ﹤0.01% |
257,642
+67,482
| +35% | +$113K |
|
3199
EVI Industries
EVI
$195M
| $427K | ﹤0.01% |
15,009
+2,083
| +16% | +$60.9K |
|
3200
Neuropace
NPCE
$465M
| $416K | ﹤0.01% |
+17,448
| New | +$405K |
|
Similar funds
Charles Schwab's Q2 2021 Portfolio in Review
As of Q2 2021, Charles Schwab held 3,648 positions worth $301B, up 10% from $273B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Charles Schwab's Q2 2021 filing shows 163 new, 2,481 increased, 676 reduced and 240 closed positions. Its largest new stake was Vanguard Intermediate-Term Treasury ETF: 6,338,757 shares worth $430M. The largest sale was iShares MBS ETF, an estimated $561M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q2 2021 buy was Vanguard Intermediate-Term Treasury ETF: 6,338,757 shares worth $430M.
- Charles Schwab added most to iShares 1-5 Year Investment Grade Corporate Bond ETF in Q2 2021, an estimated $596M increase.
- Charles Schwab's biggest Q2 2021 reduction was iShares MBS ETF, cutting an estimated $561M.
- Charles Schwab fully exited Invesco S&P 500 Low Volatility ETF in Q2 2021, selling an estimated $92.7M.
- Charles Schwab's ten largest holdings make up 17% of its $301B portfolio in Q2 2021.
- Charles Schwab opened 163 new positions and closed 240 in Q2 2021.
- Charles Schwab's portfolio value rose 10% quarter-over-quarter to $301B.
Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.